Incretin-Based Drugs Market Size, Share, Trends, Growth and Forecast 2032

Incretin-Based Drugs Market Insights

According to the report published by Zion Market Research, the global Incretin-Based Drugs Market size was valued at USD 18.33 Billion in 2023 and is predicted to reach USD 27.47 Billion by the end of 2032. The market is expected to grow with a CAGR of 4.6% during the forecast period. The report analyzes the global Incretin-Based Drugs Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Incretin-Based Drugs industry.

Request Free Sample

Global Incretin-Based Drugs Market: Overview

When the blood glucose levels decrease a group of metabolic hormones is stimulated which is known as incretins. Incretin-based drugs include glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors which are the new group of drugs that are helpful in curing type 2 diabetes. These drugs have a positive effect on the body weight and have a low risk of hypoglycemia. The oral anti-diabetic drugs are unable to maintain the desired levels of glucose, especially during the conditions of postprandial, thus increasing the requirement for a better therapeutics such as the incretin-based drugs. The consumption of the incretin-based drugs increases the secretion of insulin and inhibits the release of glucagon.

Request Free Sample

Global Incretin-Based Drugs Market: Segmentation

The global market for the incretin-based drugs is fragmented into its drug type, formulation, and distribution channel.

Depending on the drug type, the global market is segregated into dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonists.

Depending on the formulation, the market is categorized into injectable drugs and oral drugs.

Depending on the distribution channel, the market is divided into online pharmacies, hospital pharmacies, retail pharmacies, and others.

Global Incretin-Based Drugs Market: Growth Factors

The key factors that are driving the incretin-based drugs market are rising old age population, increased rate of obesity, sedentary lifestyle, increasing rate of people suffering from cardiovascular diseases and diabetes, and the increasing awareness among the people. The other factor that is driving the growth of the market is the rise in the number of patients that are undiagnosed and pre-diagnosed for the disease. There are certain factors that will restrain the growth of the market which include the absence of supportive reimbursement policies, lack of accessibility to the drugs, a high cost that is involved in the treatment and the increased safety concerns affect the market growth negatively.

Incretin-Based Drugs Market: Report Scope

Global Incretin-Based Drugs Market: Regional Analysis

According to the regional study, the global market for the incretin-based drugs is diversified into Eastern Europe, North America, Western Europe, Asia Pacific, the Middle East and Africa, and Latin America. There is an increased demand for the incretin-based drugs in the Asia Pacific region. While North America and Western European region are considered as lucrative markets for the incretin-based drugs due to the increased awareness about diabetes and the good management of the disease. The growth of the incretin-based drugs market is majorly influenced by the supportive policies that are implemented by the government. In many of countries, governments are providing support to the weaker sections of the society to have the access to diabetes drugs so that they have access to quality healthcare.

Global Incretin-Based Drugs Market: Competitive Players

The key market players that are involved in the incretin-based drugs market include:

• Boehringer Ingelheim GmbH.
• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Ltd.
• Sanofi S.A.
• AstraZeneca Plc.
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG.

The Global Incretin-Based Drugs Market is segmented as follows:
 
By Drug type 

• dipeptidyl peptidase-4 (DPP-4) inhibitors
• glucagon-like peptide-1 receptor (GLP-1) agonists

By Formulation 

• injectable drugs
• oral drugs

By Fistribution channel 

• online pharmacies
• hospital pharmacies 
• retail pharmacies
• and others

Global Incretin-Based Drugs Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.